TipRanks
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
US Market
KYMR
Kymera Therapeutics
RESEARCH TOOLSreports
Want to see KYMR full AI Analyst Report?

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

446 Followers
See the Price Targets and Ratings of:

KYMR Analyst Ratings

Strong Buy
16Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Kymera
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$141.50
▲(12.70% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $141.50 with a high forecast of $180.00 and a low forecast of $112.00. The average price target represents a 12.70% change from the last price of $125.55.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"53":"$53","85":"$85","117":"$117","149":"$149","181":"$181"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$180.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$141.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[53,85,117,149,181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,110.12,115.49538461538462,120.87076923076924,126.24615384615385,131.62153846153848,136.99692307692308,142.3723076923077,147.74769230769232,153.12307692307692,158.49846153846153,163.87384615384616,169.24923076923076,174.62461538461537,{"y":180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,110.12,112.53384615384616,114.94769230769231,117.36153846153846,119.77538461538462,122.18923076923078,124.60307692307693,127.01692307692308,129.43076923076924,131.8446153846154,134.25846153846155,136.6723076923077,139.08615384615385,{"y":141.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,110.12,110.26461538461538,110.40923076923077,110.55384615384615,110.69846153846154,110.84307692307692,110.98769230769231,111.13230769230769,111.27692307692308,111.42153846153846,111.56615384615385,111.71076923076923,111.85538461538462,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.62,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.93,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.47,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.05,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.12,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$180.00Average Price Target$141.50Lowest Price Target$112.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on KYMR
Thomas Deal
Raymond James
Not Ranked
Raymond James
$140
Buy
11.51%
Upside
Initiated
10/08/26
Kymera Therapeutics initiated with an Outperform at Raymond JamesKymera Therapeutics initiated with an Outperform at Raymond James
Citi Analyst forecast on KYMR
Geoff Meacham
Citi
Citi
$135→$150
Buy
19.47%
Upside
Reiterated
10/05/26
Kymera Therapeutics price target raised to $150 from $135 at CitiKymera Therapeutics price target raised to $150 from $135 at Citi
J.P. Morgan Analyst forecast on KYMR
Brian Cheng
J.P. Morgan
J.P. Morgan
$140
Buy
11.51%
Upside
Reiterated
09/28/26
Kymera Therapeutics placed on 'Positive Catalyst Watch' at JPMorganKymera Therapeutics placed on 'Positive Catalyst Watch' at JPMorgan
Piper Sandler Analyst forecast on KYMR
Biren Amin
Piper Sandler
Piper Sandler
$140
Buy
11.51%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Vertex Pharmaceuticals (NASDAQ: VRTX) and Nektar Therapeutics (NASDAQ: NKTR)
Stifel Nicolaus Analyst forecast on KYMR
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$132→$152
Buy
21.07%
Upside
Reiterated
09/22/26
Kymera Therapeutics price target raised to $152 from $132 at StifelKymera Therapeutics price target raised to $152 from $132 at Stifel
Bank of America Securities Analyst forecast on KYMR
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$123→$144
Buy
14.70%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR) and Intuitive Surgical (NASDAQ: ISRG)
Wolfe Research Analyst forecast on KYMR
Andy Chen
Wolfe Research
Wolfe Research
$180
Buy
43.37%
Upside
Upgraded
09/10/26
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe ResearchKymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
RBC Capital Analyst forecast on KYMR
Brian Abrahams
RBC Capital
RBC Capital
$112
Hold
-10.79%
Downside
Reiterated
09/02/26
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (NASDAQ: KYMR) and vTv Therapeutics (NASDAQ: VTVT)
Guggenheim Analyst forecast on KYMR
Bradley Canino
Guggenheim
Guggenheim
$135→$170
Buy
35.40%
Upside
Assigned
08/30/26
Kymera Therapeutics price target raised to $170 from $135 at GuggenheimKymera Therapeutics price target raised to $170 from $135 at Guggenheim
Wells Fargo Analyst forecast on KYMR
Derek Archila
Wells Fargo
Wells Fargo
$116→$151
Buy
20.27%
Upside
Assigned
08/27/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)
Canaccord Genuity Analyst forecast on KYMR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$129
Buy
2.75%
Upside
Reiterated
08/06/26
Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
H.C. Wainwright Analyst forecast on KYMR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$134
Buy
6.73%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis
Morgan Stanley Analyst forecast on KYMR
Judah Frommer
Morgan Stanley
Morgan Stanley
$119→$135
Buy
7.53%
Upside
Assigned
08/06/26
Kymera: Advancing STAT6 Pipeline, De-Risking Milestones, and Raised Price Target to $135 Support Buy Rating
Barclays Analyst forecast on KYMR
Eliana Merle
Barclays
Barclays
$133→$139
Buy
10.71%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
UBS Analyst forecast on KYMR
David Dai
UBS
UBS
$128
Buy
1.95%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Raymond James Analyst forecast on KYMR
Thomas Deal
Raymond James
Not Ranked
Raymond James
$140
Buy
11.51%
Upside
Initiated
10/08/26
Kymera Therapeutics initiated with an Outperform at Raymond JamesKymera Therapeutics initiated with an Outperform at Raymond James
Citi Analyst forecast on KYMR
Geoff Meacham
Citi
Citi
$135→$150
Buy
19.47%
Upside
Reiterated
10/05/26
Kymera Therapeutics price target raised to $150 from $135 at CitiKymera Therapeutics price target raised to $150 from $135 at Citi
J.P. Morgan Analyst forecast on KYMR
Brian Cheng
J.P. Morgan
J.P. Morgan
$140
Buy
11.51%
Upside
Reiterated
09/28/26
Kymera Therapeutics placed on 'Positive Catalyst Watch' at JPMorganKymera Therapeutics placed on 'Positive Catalyst Watch' at JPMorgan
Piper Sandler Analyst forecast on KYMR
Biren Amin
Piper Sandler
Piper Sandler
$140
Buy
11.51%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Vertex Pharmaceuticals (NASDAQ: VRTX) and Nektar Therapeutics (NASDAQ: NKTR)
Stifel Nicolaus Analyst forecast on KYMR
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$132→$152
Buy
21.07%
Upside
Reiterated
09/22/26
Kymera Therapeutics price target raised to $152 from $132 at StifelKymera Therapeutics price target raised to $152 from $132 at Stifel
Bank of America Securities Analyst forecast on KYMR
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$123→$144
Buy
14.70%
Upside
Reiterated
09/14/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR) and Intuitive Surgical (NASDAQ: ISRG)
Wolfe Research Analyst forecast on KYMR
Andy Chen
Wolfe Research
Wolfe Research
$180
Buy
43.37%
Upside
Upgraded
09/10/26
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe ResearchKymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
RBC Capital Analyst forecast on KYMR
Brian Abrahams
RBC Capital
RBC Capital
$112
Hold
-10.79%
Downside
Reiterated
09/02/26
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (NASDAQ: KYMR) and vTv Therapeutics (NASDAQ: VTVT)
Guggenheim Analyst forecast on KYMR
Bradley Canino
Guggenheim
Guggenheim
$135→$170
Buy
35.40%
Upside
Assigned
08/30/26
Kymera Therapeutics price target raised to $170 from $135 at GuggenheimKymera Therapeutics price target raised to $170 from $135 at Guggenheim
Wells Fargo Analyst forecast on KYMR
Derek Archila
Wells Fargo
Wells Fargo
$116→$151
Buy
20.27%
Upside
Assigned
08/27/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)
Canaccord Genuity Analyst forecast on KYMR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$129
Buy
2.75%
Upside
Reiterated
08/06/26
Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
H.C. Wainwright Analyst forecast on KYMR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$134
Buy
6.73%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis
Morgan Stanley Analyst forecast on KYMR
Judah Frommer
Morgan Stanley
Morgan Stanley
$119→$135
Buy
7.53%
Upside
Assigned
08/06/26
Kymera: Advancing STAT6 Pipeline, De-Risking Milestones, and Raised Price Target to $135 Support Buy Rating
Barclays Analyst forecast on KYMR
Eliana Merle
Barclays
Barclays
$133→$139
Buy
10.71%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
UBS Analyst forecast on KYMR
David Dai
UBS
UBS
$128
Buy
1.95%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

3 Months
Eliana MerleBarclays
Success Rate
8/11 ratings generated profit
73%
Average Return
+17.94%
Copying Eliana Merle's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +17.94% per trade.
1 Year
Faisal KhurshidJefferies
Success Rate
11/12 ratings generated profit
92%
Average Return
+110.98%
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +110.98% per trade.
2 Years
Faisal KhurshidJefferies
Success Rate
12/12 ratings generated profit
100%
Average Return
+181.53%
Copying Faisal Khurshid's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +181.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
5
3
1
1
1
Buy
22
22
31
22
21
Hold
0
2
3
5
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
27
35
28
25
In the current month, KYMR has received 22 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 141.50.
Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$1.27 with a range of -$1.47 to -$1.04. The previous quarter’s EPS was -$0.62. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.
Next quarter’s earnings estimate for KYMR is -$1.27 with a range of -$1.47 to -$1.04. The previous quarter’s EPS was -$0.62. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $3.10M with a range of -$1.00M to $20.00M. The previous quarter’s sales results were $65.00M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.
Next quarter’s sales forecast for KYMR is $3.10M with a range of -$1.00M to $20.00M. The previous quarter’s sales results were $65.00M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Kymera Therapeutics’s 12-month average price target is 141.50.
    What is KYMR’s upside potential, based on the analysts’ average price target?
    Kymera Therapeutics has 12.70% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KYMR a Buy, Sell or Hold?
          Kymera Therapeutics has a consensus rating of Strong Buy which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Kymera Therapeutics’s price target?
            The average price target for Kymera Therapeutics is 141.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $180.00 ,the lowest forecast is $112.00. The average price target represents 12.70% Increase from the current price of $125.55.
              What do analysts say about Kymera Therapeutics?
              Kymera Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of KYMR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.